Literature DB >> 11748735

Gastric emptying time and gastric motility in patients with Parkinson's disease.

R Hardoff1, M Sula, A Tamir, A Soil, A Front, S Badarna, S Honigman, N Giladi.   

Abstract

Gastrointestinal symptoms such as nausea, abdominal pain, and bloating are frequent complaints of patients with Parkinson's disease (PD). It has been postulated that impaired gastrointestinal function may contribute to the development of motor fluctuations such as delay on and no on in patients with PD. Gastrointestinal impaired function and symptoms may be associated with the disease itself or secondary to levodopa treatment. Thus, we assessed gastric emptying (GE) and gastric motility in PD patients to examine the association between clinical status and gastric function. GE and antral contraction (frequency and amplitude) were evaluated by scintigraphy in 29 patients with mild PD (Hoehn and Yahr [H&Y] stage 1.0-2.0); 22 patients with moderate PD (H&Y stage 2.5-3.0); and 22 healthy volunteers, following the ingestion of a labeled standard meal. Gastric emptying (mean +/- SD of T(1/2)) and antral contraction were not significantly different between patients with mild PD (63.4 +/- 28.8 minutes) and moderate PD (54.7 +/- 25.5 minutes). In the control group, GE was 43.4 +/- 10.8 minutes (range 29.0 - 61.0 minutes). The prevalence of delayed emptying (>61 minutes) was not significantly different in patients with mild disease (48.3%) as compared with patients with moderate disease (36.4%). Antral contraction, both frequency and amplitude, were not significantly different between patients with mild and moderate PD throughout the entire 100 minutes of the study. Untreated patients (n = 28) had mean GE T(1/2) of 59 +/- 30.6 minutes. Patients with smooth response to levodopa showed slower GE (n = 10; 73.6 +/- 25.3 minutes), while treated patients with motor response fluctuations when tested at the on state (n = 13), had much faster GE (49.3 +/- 16.2 minutes). This shortened GE in the on state was similar to the GE of normal volunteers. We conclude that gastric emptying time in patients with PD was delayed compared with control volunteers. It was even slower in patients treated with levodopa. This effect of levodopa treatment was reversed to pseudonormalization (normal GE) at the advanced stages of the disease, when patients developed motor response fluctuation. Other clinical features of PD were not associated with delayed gastric emptying. Copyright 2001 Movement Disorder Society.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11748735     DOI: 10.1002/mds.1203

Source DB:  PubMed          Journal:  Mov Disord        ISSN: 0885-3185            Impact factor:   10.338


  54 in total

1.  A mechanism-based approach for absorption modeling: the Gastro-Intestinal Transit Time (GITT) model.

Authors:  Emilie Hénin; Martin Bergstrand; Joseph F Standing; Mats O Karlsson
Journal:  AAPS J       Date:  2012-06       Impact factor: 4.009

2.  Therapeutic options for continuous dopaminergic stimulation in Parkinson's disease.

Authors:  O K Sujith; Carol Lane
Journal:  Ther Adv Neurol Disord       Date:  2009-03       Impact factor: 6.570

3.  Mice overexpressing wild-type human alpha-synuclein display alterations in colonic myenteric ganglia and defecation.

Authors:  L Wang; I Magen; P-Q Yuan; S R Subramaniam; F Richter; M-F Chesselet; Y Taché
Journal:  Neurogastroenterol Motil       Date:  2012-07-11       Impact factor: 3.598

4.  Meta-analysis of Magnetic Marker Monitoring Data to Characterize the Movement of Single Unit Dosage Forms Though the Gastrointestinal Tract Under Fed and Fasting Conditions.

Authors:  Emilie Hénin; Martin Bergstrand; Werner Weitschies; Mats O Karlsson
Journal:  Pharm Res       Date:  2015-11-09       Impact factor: 4.200

5.  The use of enteral access for continuous delivery of levodopa-carbidopa in patients with advanced Parkinson's disease.

Authors:  Julian Cheron; Jacques Deviere; Frederic Supiot; Asuncion Ballarin; Pierre Eisendrath; Emmanuel Toussaint; Vincent Huberty; Carmen Musala; Daniel Blero; Arnaud Lemmers; André Van Gossum; Marianna Arvanitakis
Journal:  United European Gastroenterol J       Date:  2016-06-23       Impact factor: 4.623

Review 6.  Gastrointestinal features of Parkinson's disease.

Authors:  Leslie J Cloud; James G Greene
Journal:  Curr Neurol Neurosci Rep       Date:  2011-08       Impact factor: 5.081

7.  Unchanged gastric emptying and visceral perception in early Parkinson's disease after a high caloric test meal.

Authors:  L Epprecht; S R Schreglmann; O Goetze; D Woitalla; C R Baumann; D Waldvogel
Journal:  J Neurol       Date:  2015-06-06       Impact factor: 4.849

8.  Association between DRD2 and DRD3 gene polymorphisms and gastrointestinal symptoms induced by levodopa therapy in Parkinson's disease.

Authors:  M Rieck; A F Schumacher-Schuh; V Altmann; S M Callegari-Jacques; C R M Rieder; M H Hutz
Journal:  Pharmacogenomics J       Date:  2016-10-25       Impact factor: 3.550

9.  Clinical and pharmacokinetics equivalence of multiple doses of levodopa benserazide generic formulation vs the originator (Madopar).

Authors:  Margherita Torti; Jhessica Alessandroni; Daniele Bravi; Miriam Casali; Paola Grassini; Chiara Fossati; Cristiano Ialongo; Marco Onofrj; Fabiana Giada Radicati; Laura Vacca; Stefano Bonassi; Fabrizio Stocchi
Journal:  Br J Clin Pharmacol       Date:  2019-09-12       Impact factor: 4.335

Review 10.  Oral and infusion levodopa-based strategies for managing motor complications in patients with Parkinson's disease.

Authors:  Angelo Antonini; K Ray Chaudhuri; Pablo Martinez-Martin; Per Odin
Journal:  CNS Drugs       Date:  2010-02       Impact factor: 5.749

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.